03/08/2026 Akebia Therapeutics announced the initiation of a Phase 2 basket trial evaluating ebribafusp in rare complement-mediated kidney disease Akebia Therapeutics announced the initiation of a Phase 2 basket trial evaluating ebribafusp in rare complement-mediated kidney disease (Ref) Akebia Therapeutics announced the initiation of a Phase 2/ NCT06419205 basket trial evaluating the safety, efficacy and pharmacokinetics of ebribafusp (AKB-097 and ADX-097; anti-C3d factor H

06/08/2026 Biogen completed the acquisition of RayThera to strengthen its immunology pipeline Ono Pharmaceutical entered into a drug discovery partnership with Mediar Therapeutics to create novel antibody therapeutics for fibro-inflammatory diseases Biogen completed the acquisition of RayThera to strengthen its immunology pipeline (Ref) Biogen announced the completion of its acquisition of RayThera a biotechnology company focused on discovering and developing small-molecule t

30/07/2026 CREATE Medicines announced that it had received approval to initiate a Phase 1/2 trial of CRT-402 for autoimmune diseases Pfizer announced topline Phase 3 results for LITFULO in Patients with Nonsegmental Vitiligo CREATE Medicines announced that it had received approval to initiate a Phase 1/2 trial of CRT-402 for autoimmune diseases (Ref) CREATE Medicines announced that it had received Human Research Ethics Committee (HREC) approval in Australia to begin its Phase

29/07/2026 AbbVie announced European Commission approval of RINVOQ® for non-segmental vitiligo AbbVie announced European Commission approval of RINVOQ® for severe alopecia areata Johnson & Johnson announced a strategic collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for autoimmune diseases AbbVie announced European Commission approval of RINVOQ® for non-segmental vitiligo (Ref) AbbVie announced that the European Commission (EC) approved RINVOQ® (upadac

27/07/2026 Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline InnoCare's fadeucravacitinib met it primary endpoint in Phase 3 Psoriasis study Jacobio dosed the first patient in China in Phase 2a trial of JAB-8263 for Rheumatoid arthritis Bambusa Therapeutics reported preliminary Proof-of-concept data for BTT001 in Atopic Dermatitis Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline (Ref) Argenx announced that the compa

24/07/2026 Sanofi announced its decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews Sanofi announced its decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews (Ref) Sanofi announced the discontinuation of clinical development of amlitelimab (OX40-ligand) in moderate-to-severe atopic dermatitis (AD). The decision followed a strategic pipeline review, that concluded the overall efficacy and safety data did not su

21/07/2026 Nektar Therapeutics initiated the Phase 3 ZENITH AD Program evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis Nektar Therapeutics initiated the Phase 3 ZENITH AD Program evaluating rezpegaldesleukin in moderate-to-severe atopic dermatitis (Ref) Nektar Therapeutics announced the initiation of the two global registrational Phase 3, ZENITH AD-1 and ZENITH AD-2 trials evaluating rezpegaldesleukin (IL-2 receptor agonist) in patients who were ≥12 year

20/07/2026 AbelZeta received EMA PRIME designation for C-CAR168 in LN and SLE LAPIX Therapeutics completed patient enrollment in the RA arm of the ongoing LPX-TI641 clinical trial Almirall announced EMA acceptance of the pediatric filing for Ebglyss® in atopic dermatitis AbelZeta received EMA PRIME designation for C-CAR168 in LN and SLE (Ref) AbelZeta Pharma announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had granted

17/07/2026 European Commission approved JASCAYD® as a treatment option for IPF and PPF in the EU Novartis received FDA traditional approval for Fabhalta® for the treatment of primary IgAN European Commission approved JASCAYD® as a treatment option for IPF and PPF in the EU (Ref) Boehringer Ingelheim announced that the European Commission had granted marketing authorization for JASCAYD® (nerandomilast; PDE4B inhibitor) for the treatment of adults with idiopathic pulmonary fibr

15/07/2026 FDA granted priority review to Roche’s Gazyva for adults with primary membranous nephropathy InnoCare reported Phase 3 results for soficitinib in atopic dermatitis FDA granted priority review to Roche’s Gazyva for adults with primary membranous nephropathy (Ref) Roche announced that the US FDA had granted priority review to the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab; anti-CD20) for the treatment of primary me

14/07/2026 Innovent Biologics and Spero Therapeutics announced an exclusive licensing agreement for IBI355 for the treatment of immune-mediated diseases Innovent Biologics and Spero Therapeutics announced an exclusive licensing agreement for IBI355 for the treatment of immune-mediated diseases (Ref) Innovent Biologics and Spero Therapeutics announced an exclusive license agreement for IBI355 (SP001; a third-generation Fc-silent anti-CD40L antibody) for immune-mediated disease

13/07/2026 Novartis received Health Canada approval for VANRAFIA™ to reduce proteinuria in adults with primary IgAN IQIRVO® demonstrated statistically significant improvement in ALP normalization in patients with PBC in Phase 3b study Q32 Bio announced results from Part B of the Phase 2a study of bempikibart in Alopecia Areata Novartis received Health Canada approval for VANRAFIA™ to reduce proteinuria in adults with primary IgAN (Ref) Novartis Pharmaceuticals Canada announce

09/07/2026 LEO Pharma announced Phase 2 results of tralokinumab in children with moderate-to-severe atopic dermatitis Fate Therapeutics received FDA clearance of its IND Application for FT839 in autoimmune LEO Pharma announced Phase 2 results of tralokinumab in children with moderate-to-severe atopic dermatitis (Ref) LEO Pharma announced positive results from the Phase 2, TRAPEDS-1 trial evaluated tralokinumab (Anti-IL-13) in children aged 6 to 11 years with moderate-to-sever

08/07/2026 Merck announced that the US FDA had granted Breakthrough Therapy designation to enpatoran Chemomab Therapeutics and Scipher Medicine announced a merger to advance nebokitug in an AI-powered Phase 2 Rheumatoid Arthritis study Merck announced that the US FDA had granted Breakthrough Therapy designation to enpatoran (Ref) Merck announced that the US FDA had granted Breakthrough Therapy designation to enpatoran (TLR 7/8 inhibitor) for the treatment of lupus with active

07/07/2026 Vera Therapeutics announced US FDA accelerated approval of TRUTAKNA™ for adults with primary IgA nephropathy Turn Therapeutics announced the final stage 2 design and data-driven expansion of the GX-03 phase 2 trial in Atopic Dermatitis Everest Medicines announced the closing of its exclusive licencing agreement with Travere Therapeutics for civorebrutinib Vera Therapeutics announced US FDA accelerated approval of TRUTAKNA™ for adults with primary IgA nephropathy (R

06/07/2026 Aurinia announced the initiation of a Phase 4 study investigating the combination of voclosporin and belimumab, obinutuzumab or anifrolumab in patients with LN Aurinia announced the initiation of a Phase 4 study investigating the combination of voclosporin and belimumab, obinutuzumab or anifrolumab in patients with LN (Ref) Aurinia Pharmaceuticals announced the initiation of the Phase 4, PRESERVE/ NCT07611214 study investigating the combination of LUPKYNIS® (voclos

01/07/2026 Ostuka reported positive Phase 3 results for sibeprenlimab in IgAN Ostuka reported positive Phase 3 results for sibeprenlimab in IgAN (Ref) Otsuka Pharmaceutical announced positive topline full study results from the Phase 3, VISIONARY/ NCT05248646 trial for VOYXACT® (sibeprenlimab-szsi; Anti-APRIL) in adults with primary IgA nephropathy (IgAN) at risk of disease progression. Sibeprenlimab demonstrated statistically significant stabilization of eGFR with evidence

30/06/2026 FDA granted priority review to Roche’s satralizumab as a treatment option for TED FDA granted priority review to Roche’s satralizumab as a treatment option for TED (Ref) Roche announced that the US FDA had accepted and granted priority review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) for the treatment of thyroid eye disease (TED). The filing acceptance was based on results from the two randomized phase 3, SatraGO-1/ NCT0598

29/06/2026 Abbvie received positive CHMP opinion for upadacitinib for the treatment of adults and adolescents with Non-segmental Vitiligo Abbvie received positive CHMP opinion for upadacitinib for the treatment of adults and adolescents with severe alopecia areata Zura Bio exceeded Phase 2 enrollment target for HS and SSc and expanded tibulizumab program Dianthus Therapeutics announced the initiation of a Phase 3 trial of claseprubart in gMG Abivax announced ABETACT maintenan

26/06/2026 SKYRIZI® received US FDA approval for pediatric psoriatic disease Viridian Therapeutics announced US FDA approval and commercial launch of Lumvoa™ for Thyroid Eye Disease SKYRIZI® received US FDA approval for pediatric psoriatic disease (Ref) AbbVie announced that the US FDA had approved SKYRIZI® (risankizumab-rzaa; IL-23 inhibitor) for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic ther